Amgen (AMGN) Tops Q3 EPS by 25c, Offers Guidance

Amgen (NASDAQ: AMGN) reported Q3 EPS of $4.70, $0.25 better than the analyst estimate of $4.45. Revenue for the quarter came in at $6.7 billion versus the consensus estimate of $6.58 billion.

GUIDANCE:

Amgen sees FY2022 EPS of $17.25-$17.85, versus the consensus of $17.50. Amgen sees FY2022 revenue of $26-26.3 billion, versus the consensus of $26.14 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
• AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
• Canaccord Reiterates Hold Rating on Amgen (AMGN)